Clinical Trial Search

Primary: Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM. — -20.4 mm Hg — p=<0.0001

Primary: Number of Subjects With an Immune Response to a Challenge Dose of Hepatitis B Vaccine — 28 subjects

Primary: Proportion of Patients With a Clinically Significant Increase in Oral Body Temperature or Use of Rescue Medication. — 0.607; 0.398; 0.618; 0.39 proportion of patients

Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment — -25.7 mm Hg — p=<0.0001

Primary: Number of Participants With Laboratory-Confirmed Clinical Influenza, ITT Population — 7; 5 participants — p=0.772

Primary: Sustained Virologic Response — 87; 117 participants — p=< 0.001

Primary: Number of Patients With Healed Fractures — 83; 66; 8; 13 patients — p=0.0541

Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population — -2.01; -1.75 percent — p=<0.0001

Primary: Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus — 1.925; 2.177 Log(mg*hr/dl) — p=0.03

Primary: Number of Participants With Clinical Success at Month 24/Discontinuation — 21; 36; 0.808; 0.632 patients

Primary: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only) — 916; 898 Participants — p=0.7830

Primary: Assessment of Facial Irritation and Cutaneous Effects — 4.8; 3.9; 8.8; 6.7 Ordinal data treated as interval

Primary: Weighted Mean Change From Baseline Over 0-6 Hours in Blood Eosinophils Post-Allergen Challenge on Day 35 — -0.050; -0.040; -0.023 Giga Units per Liter (GI/L)

Primary: Change From Baseline in Total Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Score at 7 Weeks — -28.6 Units on a scale — p=< 0.0001

Primary: Percentage of Participants With Solicited Local and Systemic Reactions After Fluzone® Vaccination — 60; 23; 8; 5 Percentage of Participants